ASCO 2019 | Atezolizumab for TNBC
Erika Hamilton
Erika Hamilton, MD, of the Sarah Cannon Research Institute, Nashville. TN, discusses the use of
atezolizumab for the treatment of triple-negative breast cancer (TNBC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
Related videos
5:04 Is age a barrier for chemotherapy?
Nicolo Battisti
2:53 Supporting patients through genetic testing
Maria Katapodi
3:56 Radiation on tumor antigenicity and adjuvanticity
Sandra Demaria
1:56 Challenges with chemotherapy in older patients
Nicolo Battisti
2:15 Other factors to consider with radiation effects on tumor antigenicity and adjuvanticity
Sandra Demaria
